ANI Pharmaceuticals (NASDAQ:ANIP) Share Price Crosses Below 50-Day Moving Average – Time to Sell?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) shares passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $81.82 and traded as low as $81.11. ANI Pharmaceuticals shares last traded at $81.33, with a volume of 774,567 shares traded.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Barclays started coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price objective for the company. Guggenheim lifted their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Truist Financial boosted their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Finally, Zacks Research cut shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $103.43.

ANI Pharmaceuticals Stock Performance

The company has a market capitalization of $1.83 billion, a PE ratio of 49.90 and a beta of 0.51. The stock’s fifty day simple moving average is $81.82 and its 200-day simple moving average is $84.78. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.04 and a current ratio of 2.58.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Insider Buying and Selling

In other ANI Pharmaceuticals news, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This represents a 6.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Patrick D. Walsh sold 8,643 shares of the firm’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $86.88, for a total value of $750,903.84. Following the sale, the director owned 61,405 shares in the company, valued at $5,334,866.40. This trade represents a 12.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 28,101 shares of company stock worth $2,453,063 in the last three months. 12.70% of the stock is currently owned by insiders.

Institutional Trading of ANI Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the period. Advisors Asset Management Inc. acquired a new position in ANI Pharmaceuticals during the first quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd increased its position in ANI Pharmaceuticals by 4,636.4% during the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock worth $34,000 after purchasing an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. raised its stake in ANI Pharmaceuticals by 200.0% during the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 400 shares during the period. Finally, State of Wyoming acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.